Aligos Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Aligos Therapeutics' es Larry Blatt , nombrado en Feb 2018, tiene una permanencia de 6.17 años. compensación anual total es $1.85M, compuesta por 29.6% salario y 70.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.8% de las acciones de la empresa, por valor de $1.76M. La antigüedad media del equipo directivo y de la junta directiva es de 5.2 años y 5.7 años, respectivamente.
Información clave
Larry Blatt
Chief Executive Officer (CEO)
US$1.3m
Compensación total
| Porcentaje del salario del CEO | 43.7% |
| Permanencia del CEO | 6.3yrs |
| Participación del CEO | 2.8% |
| Permanencia media de la dirección | 5.3yrs |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Dosing underway for Aligos Therapeutics' hepatitis B candidate in early-stage study
Oct 30Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$100m |
| Dec 31 2023 | US$1m | US$587k | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$82m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$83m |
| Dec 31 2022 | US$2m | US$549k | -US$96m |
| Sep 30 2022 | n/a | n/a | -US$112m |
| Jun 30 2022 | n/a | n/a | -US$126m |
| Mar 31 2022 | n/a | n/a | -US$136m |
| Dec 31 2021 | US$873k | US$549k | -US$128m |
| Sep 30 2021 | n/a | n/a | -US$125m |
| Jun 30 2021 | n/a | n/a | -US$125m |
| Mar 31 2021 | n/a | n/a | -US$116m |
| Dec 31 2020 | US$7m | US$493k | -US$109m |
| Sep 30 2020 | n/a | n/a | -US$92m |
| Jun 30 2020 | n/a | n/a | -US$73m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$674k | US$475k | -US$52m |
Compensación vs. Mercado: La compensación total de Larry($USD1.85M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Larry ha sido consistente con los resultados de la empresa en el último año.
CEO
Larry Blatt (61 yo)
6.3yrs
Permanencia
US$1,344,458
Compensación
Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 6.3yrs | US$1.34m | 2.75% $ 1.6m | |
| Executive VP & Chief Scientific Officer | 6yrs | US$836.32k | 0.50% $ 287.8k | |
| Executive VP & Chief Medical Officer | 4.8yrs | US$837.72k | 0.12% $ 67.5k | |
| Executive VP & CFO | 3.9yrs | sin datos | sin datos | |
| VP and Head of People & Culture | 2.3yrs | sin datos | sin datos | |
| Executive Vice President & Chief Development Officer | 5.8yrs | sin datos | sin datos | |
| Executive VP & Head of Chemical Operations | 5.8yrs | sin datos | sin datos | |
| VP of Early Compound Development & Belgian Site Head | 2.3yrs | sin datos | sin datos |
5.3yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ALGS es experimentado (5.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman of the Board | 6.3yrs | US$1.34m | 2.75% $ 1.6m | |
| Independent Director | 5.8yrs | US$12.90k | 0% $ 0 | |
| Lead Independent Director | 5.8yrs | US$93.40k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$67.90k | 0.23% $ 133.7k | |
| Independent Director | 2.5yrs | US$52.90k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$60.40k | 0.076% $ 43.5k |
5.8yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de ALGS se considera experimentada (5.7 años de antigüedad promedio).